ORPHAN DESIGNATIONS AND APPROVALS IN THE EU, UNITED STATES AND JAPAN

被引：3
|
作者：
Korchagina, D. [1 ]
Tomita, N. [2 ]
Falissard, B. [3 ]
Toumi, M. [4 ]
Tavella, F. [5 ]
机构：
[1] Univ Paris Sud, Paris, France
[2] Natl Inst Publ Hlth, Saitama, Japan
[3] Maison Solenn, Paris, France
[4] Aix Marseille Univ, Marseille, France
[5] Creat Ceut, London, England
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.147
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EA4
引用
收藏
页码：A341 / A341
页数：1
相关论文
共 50 条
  • [1] ANALYSIS OF ORPHAN DRUG DESIGNATIONS AND APPROVALS IN THE UNITED STATES AND THE EUROPEAN UNION
    Almutairi, R. D.
    Alghamdi, A. A.
    Felemban, D. F.
    Seoane-Vazquez, E.
    Rodriguez-Monguio, R.
    Szeinbach, S. L.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A124 - A124
  • [2] COMPARISON OF THE TRENDS OF ORPHAN DRUGS DESIGNATIONS AND APPROVALS IN THE UNITED STATES AND EUROPE IN ONCOLOGY
    Hanna, E.
    Korchagina, D.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A892 - A892
  • [3] Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan
    Murakami, Manabu
    Narukawa, Mamoru
    [J]. DRUG DISCOVERY TODAY, 2016, 21 (04) : 544 - 549
  • [4] THE LANDSCAPE OF US ORPHAN PRODUCT DESIGNATIONS AND APPROVALS
    Althobaiti, H.
    Rodriguez-Monguio, R.
    Brown, L.
    Seoane-Vazquez, E.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S470 - S470
  • [5] Orphan drug approvals of 2015: Europe and the United States
    Norman, Peter
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (05): : 491 - 500
  • [6] Orphan drug approvals of 2014: Europe and the United States
    Norman, Peter
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (04): : 445 - 455
  • [7] Despite surge in orphan drug designations, approvals still lag
    Heger, Monica
    [J]. NATURE MEDICINE, 2011, 17 (03) : 236 - 236
  • [8] Despite surge in orphan drug designations, approvals still lag
    Monica Heger
    [J]. Nature Medicine, 2011, 17 : 236 - 236
  • [9] THE RISE OF ORPHAN DRUGS IN EUROPE VS THE UNITED STATES: COMPARING ORPHAN DRUG DESIGNATIONS BETWEEN THE EMA AND FDA
    Mildred, M.
    Lee, S.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A677 - A677
  • [10] PATIENT-REPORTED OUTCOME CLAIMS IN EUROPEAN AND UNITED STATES ORPHAN DRUG APPROVALS
    Jaroslawski, S.
    Toumi, M.
    Auquier, P.
    Dussart, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S109 - S109
12345